HFNC vs. NIV in Acute Cardiogenic Pulmonary Edema: Go with the Flow?

This trial adds meaningful insight into a common real-world dilemma: can high-flow nasal cannula (HFNC) replace NIV in acute cardiogenic pulmonary edema (ACPE)? The authors demonstrated no significant difference in respiratory rate reduction, dyspnea score improvement, blood gas correction, or hospitalization rates at 120 minutes between HFNC and NIV. While not powered for mortality or intubation rates, their findings support HFNC performing similarly to NIV in the early management of ACPE.

PEEP vs High Flow: Theoretically, NIV should outperform HFNC in pulmonary edema because it provides higher positive pressure (PEEP) to recruit alveoli and reduce left ventricular afterload. However, this study suggests that for moderate ACPE, the modest PEEP generated by HFNC (approx. 2–5 cmH₂O depending on mouth closure) combined with high-flow dead space washout is clinically equivalent to NIV in the first two hours.

Why Patients Switched: The pattern of treatment failure tells the real story regarding the 29 crossovers. Patients switched from HFNC to NIV (16) exclusively due to physiological failure (lack of efficacy or clinical impairment). In contrast, most switches from NIV to HFNC (13) were driven by mask intolerance/discomfort (8), rather than clinical failure. This suggests HFNC may be a reasonable starting point for some patients, but clinicians must be ready to escalate given NIV is able to provide more physiological support and has less clinical failure.

Who Still Needs NIV?: HFNC is not a “set and forget” strategy for the sickest patients. It is not ideal for severe presentations such as:

    ◦ SCAPE or sympathetic crashing pulmonary edema
    ◦ Severe hypercarbia with pH <7.25
    ◦ Impending respiratory fatigue.

In these cases, NIV remains the preferred strategy, as positive pressure is physiologically necessary to recruit alveoli and unload the left ventricle. Furthermore, patients with altered mental status (GCS ≤13) were specifically excluded from this trial. In this population, NIV carries a high risk of aspiration, and early endotracheal intubation is often the safest course.

Medical Management: A major confounder is the medical management parameters. The study notes patients received “standard” diuretics and nitrates but provides no protocol on dosing. In SCAPE and ACPE, aggressive medical bundles (diuretics, vasodilators and afterload reduction) often do the “heavy lifting” in physiological improvement. If medical management was aggressive, the choice of oxygen device may become secondary; if medical management was weak or delayed, the device matters more. Without these details, it is hard to know if HFNC worked because it is great, or because the drugs worked regardless of the device.

Resources: One of the most interesting points in the trial was the exclusion of two patients because the hospital physically ran out of ventilator sets. This highlights a critical logistical and resource challenge. If an academic center with a resource supported trial can run low on NIV, smaller community sites may struggle with the same in surge scenarios. At institutions like mine (UTHealth Houston), HFNC is readily available in the ED and step-down units — even still, NIV remains the default in severe cardiogenic pulmonary edema, particularly when nitroglycerin/BiPAP bundles are implemented. HFNC importantly requires less intensive nursing/RT supervision than NIV. In resource-limited settings (or pandemics), HFNC can be a viable first step if closely monitored.

Patient Tolerance: From a practical standpoint, HFNC allows patients to speak, eat, and clear secretions—activities impossible with a tight-fitting NIV mask. For elderly patients or those in palliative scenarios, this comfort factor may outweigh the marginal physiologic benefits of NIV.

Short-Term Data Only: The study’s 120-minute cutoff creates a significant blind spot regarding “late failure.” While HFNC was non-inferior within the first two hours, we lack data on downstream markers like ICU admission, length of stay, or mortality. For the patient, this implies that HFNC is effective at stabilizing the acute presentation, but we lack evidence that it provides the longer term stability needed to prevent intubation if the pulmonary edema does not resolve rapidly with medical management. In this way it may act as an early bridge therapy in more prolonged cases.

In Practice: In a high-volume ED, HFNC can offer a logistical advantage by being easier to initiate and better tolerated than NIV. However, this ease of use must not lead to a “set and forget” mentality. In this trial, nearly 18% of HFNC patients required escalation to NIV due to lack of efficacy or clinical deterioration. In my clinical bedside practice, there are routine patients who fail HFNC despite meeting criteria and tolerating it initially. Therefore, while HFNC is a valid first-line option or “bridge” for moderate ACPE, it mandates strict reassessment. If the patient hasn’t shown clear clinical and physiologic improvement, clinicians must be ready to immediately escalate to NIV or intubation. One may argue that given the resources associated with escalation, in a busy low resource environment it may be reasonable to start on NIV and de-escalate to HFNC as patients clinically improve.